Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 14/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.65 |
| ▸ | SLC2A9 | Q9NRM0 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | IL15 | P40933 | 1/20 | 0.41 |
| ▸ | IL2 | P60568 | 1/20 | 0.41 |
| ▸ | IL15RA | Q13261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376753 | 1.00 | SLC22A12 (0.65) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Potassium SCHEMBL30892115 | 0.99 | SLC22A12 (0.64) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL14921536 | 0.99 | SLC22A12 (0.64) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL248724 | 0.93 | SLC22A12 (0.62) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Potassium Ion SCHEMBL14921535 | 0.92 | SLC22A12 (0.61) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Potassium Ion SCHEMBL30014976 | 0.92 | SLC22A12 (0.61) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL249359 | 0.91 | SLC22A12 (0.51) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL10029197 | 0.91 | SLC22A12 (0.51) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL1719573 | 0.91 | SLC22A12 (0.65) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL12056187 | 0.90 | SLC22A12 (0.64) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190142805-A1 | Novel Compounds and Compositions and Methods of Use | ARDEA BIOSCIENCES INC. | 2019-05-16 | — | — | US | claimed |
| US-20160221970-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2016-08-04 | — | — | US | claimed |
| US-20140005136-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2014-01-02 | — | — | US | claimed |
| US-20120077981-A1 | N[S(4-ARYL-TRIAZOL-3-YL)ALPHA-MERCAPTOACETYL]-P-AMINO BENZOIC ACIDS AS HIV REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC. (US) | 2012-03-29 | — | — | US | claimed |
| EP-1789039-B1 | S-TRIAZOLYL ALPHA -MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES INC (US) | 2012-01-11 | — | — | EP | claimed |
| US-7435752-B2 | N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]-p-amino benozioc acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2008-10-14 | — | — | US | claimed |
| WO-2007050087-A1 | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2007-05-03 | — | — | WO | claimed |
| US-20060270725-A1 | N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. | 2006-11-30 | — | — | US | claimed |
| US-20190142805-A1 | Novel Compounds and Compositions and Methods of Use | ARDEA BIOSCIENCES INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190142805-A1 | Novel Compounds and Compositions and Methods of Use | ARDEA BIOSCIENCES INC. | 2019-05-16 | — | — | US | disclosed |
| US-10183012-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-10183012-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180134670-A1 | CARBOXYLIC ACID URAT1 INHIBITOR CONTAINING DIARYLMETHANE STRUCTURE, PREPARATION METHOD AND USE THEREOF | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2018-05-17 | — | — | US | disclosed |
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | ARDEA BIOSCIENCES, INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1789039-A2 | S-TRIAZOLYL ALPHA -MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | Ardea Biosciences, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007050087-A1 | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050087-A1 | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20060270725-A1 | N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006026356-A2 | S-TRIAZOLYL α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005136-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-20120077981-A1 | N[S(4-ARYL-TRIAZOL-3-YL)ALPHA-MERCAPTOACETYL]-P-AMINO BENZOIC ACIDS AS HIV REVERSE TRANSCRIPTASE INHIBITORS | NQO2, NAT1, QPCT | SLC22A12 1704/4885CYP2C9 1434/4885CYP2C19 1933/4885 |
| US-20060270725-A1 | N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors | NQO2, NAT1, QPCT | SLC22A12 1704/4885CYP2C9 1434/4885CYP2C19 1933/4885 |
| US-10183012-B2 | Compounds and compositions and methods of use | XDH, PON1, OAT | SLC22A12 815/4885CYP2C9 762/4885CYP2C19 905/4885 |
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | SLC22A12 1639/4885CYP2C9 493/4885CYP2C19 847/4885 |
| US-20180134670-A1 | CARBOXYLIC ACID URAT1 INHIBITOR CONTAINING DIARYLMETHANE STRUCTURE, PREPARATION METHOD AND USE THEREOF | SLC10A1, SLCO2A1, SLCO2B1 | SLC22A12 55/4885CYP2C9 621/4885CYP2C19 1232/4885 |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | SPR, POLR2H, QTRT1 | SLC22A12 1536/4885CYP2C9 381/4885CYP2C19 660/4885 |
| US-20160221970-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-20190142805-A1 | Novel Compounds and Compositions and Methods of Use | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.